Safety and efficacy of favipiravir for the management of COVID-19 patients: A preliminary randomized control trial
S M Abdur Rahman, Ahmedul Kabir, Md Abm B M Abdullah, Md Billal Alam, Khan Abul Kalam Azad, Md Titu Miah, Syed Ghulam Mogni Mowla, Sudip Ranjan Deb, Mohammad Robed Amin, Muhammad Asaduzzaman
Clinical Infection in Practice, doi:10.1016/j.clinpr.2022.100145
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Table-5: Assessment of Adverse effects of patients of both groups 4%) 0 (0%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Jaundice 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Skin rash 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Liver damage 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2(8%) 0 (0%) 1 (4%) Anemia 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Vertigo 2 (8%) 2 (8%) 2 (8%) 2 (8%) 0 (0%) 2 (8%) 0 (0%) 1 (4%) Anosmia 1 (4%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Conflict of Interest: The authors declared that there was no conflict of interest regarding the clinical trial. Funding: Beacon Pharmaceuticals Limited, Dhaka, Bangladesh.
References Author Contributions:
References
Alam, Kamal, Sarkar, Zhou, Rahman et al., Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021, Front Pharmacol,
doi:10.3389/fphar.2021.659577Cucinotta, Vanelli, WHO declares COVID-19 a pandemic, Acta Biomed
Delang, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, Antiviral Res
Du, Chen, Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clinical Pharmacology and Therapeutics
Filho, Covid-19 and the UN Sustainable Development Goals: Threat to Solidarity or an Opportunity?, Sustainability,
doi:10.3390/su12135343Furuta, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci
Furuta, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Scientific reports
Hossain, Hridoy, Rahman, Ahmad, Major depressive and Generalized anxiety disorders among university students during the second wave of COVID-19 outbreak in Bnagladesh. Asia Pac, J. Pubic Health
Hossain, Rahman, Repurposing therapeutic agents againsts SARS-CoV-2 infection: most promising and neoteric progress, Expert Rev Antiinfective Therapy,
doi:10.1080/14787210.2021.1864327Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Li, Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat Rev Drug Discov
Lu, Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle, J Med Virol,
doi:10.1002/jmv.25678Nicola, The Socio-economic implications of the coronavirus pandemic (COVID-19): A review, Int. J. Surg
Nigata, Favipiravir: a new medication for the ebola virus disease pandemic, Disaster Medicine and Public Health preparedness
Pilkington, A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?, J. Virus Erad
Roser, Coronavirus Disease (COVID-19)-Statistics and Research
Sleeman, In vitro antiviral activity of favipiravir (T-705 ) against drug-resistant influenza and 2009 a (H1N1) viruses, Antimicrob Agents Chemother
Wang, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019nCoV) in vitro, Cell Res
Weiss, Murdoch, Clinical course and mortality risk of severe COVID-19, Lancet
Zhou, Clinical course and risk factors mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study, Lancet
